Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Trial Profile

Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs BIM 23A760 (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Therapeutic Use
  • Acronyms CAMPANULA
  • Sponsors Ipsen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Mar 2012 This trial has been completed in Ireland, Belgium and recruiting in France.
    • 09 Mar 2011 United Kingdom Clinical Research Network record reports trial status as completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top